Terms: = Ovarian cancer AND FANCG, ENSG00000221829, 2189, O15287, XRCC9, FAG
16 results:
1. The identification of six risk genes for ovarian cancer platinum response based on global network algorithm and verification analysis.
Xing L; Mi W; Zhang Y; Tian S; Zhang Y; Qi R; Lou G; Zhang C
J Cell Mol Med; 2020 Sep; 24(17):9839-9852. PubMed ID: 32762026
[TBL] [Abstract] [Full Text] [Related]
2. Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: A systematic review of the literature.
Morrison A; Nasioudis D
Gynecol Oncol; 2020 Aug; 158(2):476-483. PubMed ID: 32513565
[TBL] [Abstract] [Full Text] [Related]
3. Analysis of polymorphisms in genes associated with the FA/BRCA pathway in three patients with multiple primary malignant neoplasms.
Wang L; Wang H; Wang T; Liu J; Chen W; Wang Y; Chen C; Zhu H; Dai P
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1101-1112. PubMed ID: 30942098
[TBL] [Abstract] [Full Text] [Related]
4. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.
Schubert S; van Luttikhuizen JL; Auber B; Schmidt G; Hofmann W; Penkert J; Davenport CF; Hille-Betz U; Wendeburg L; Bublitz J; Tauscher M; Hackmann K; Schröck E; Scholz C; Wallaschek H; Schlegelberger B; Illig T; Steinemann D
Int J Cancer; 2019 Jun; 144(11):2683-2694. PubMed ID: 30426508
[TBL] [Abstract] [Full Text] [Related]
5. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and ovarian cancer.
Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E
Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266
[TBL] [Abstract] [Full Text] [Related]
6. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
[TBL] [Abstract] [Full Text] [Related]
7. A comparison of overall survival with 40 and 50mg/m
Nakayama M; Kobayashi H; Takahara T; Nishimura Y; Fukushima K; Yoshizawa K
Gynecol Oncol; 2016 Nov; 143(2):246-251. PubMed ID: 27612976
[TBL] [Abstract] [Full Text] [Related]
8. The Relationship between Intraoperative Rupture and Recurrence of Pediatric ovarian Neoplasms: Preliminary Observations.
Yousef Y; Pucci V; Emil S
J Pediatr Adolesc Gynecol; 2016 Apr; 29(2):111-6. PubMed ID: 26300232
[TBL] [Abstract] [Full Text] [Related]
9. Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples.
Patterson MJ; Sutton RE; Forrest I; Sharrock R; Lane M; Kaufmann A; O'Donnell R; Edmondson RJ; Wilson BT; Curtin NJ
Br J Cancer; 2014 Jul; 111(1):94-100. PubMed ID: 24867690
[TBL] [Abstract] [Full Text] [Related]
10. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.
Kennedy RD; Chen CC; Stuckert P; Archila EM; De la Vega MA; Moreau LA; Shimamura A; D'Andrea AD
J Clin Invest; 2007 May; 117(5):1440-9. PubMed ID: 17431503
[TBL] [Abstract] [Full Text] [Related]
11. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Snyder ER; Ricker JL; Chen Z; Waes CV
Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
[TBL] [Abstract] [Full Text] [Related]
12. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.
Macleod K; Mullen P; Sewell J; Rabiasz G; Lawrie S; Miller E; Smyth JF; Langdon SP
Cancer Res; 2005 Aug; 65(15):6789-800. PubMed ID: 16061661
[TBL] [Abstract] [Full Text] [Related]
13. Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot.
Van Der Heijden MS; Brody JR; Kern SE
Cancer Biol Ther; 2004 Jun; 3(6):534-7. PubMed ID: 15107617
[TBL] [Abstract] [Full Text] [Related]
14. Fanconi anemia gene mutations in young-onset pancreatic cancer.
van der Heijden MS; Yeo CJ; Hruban RH; Kern SE
Cancer Res; 2003 May; 63(10):2585-8. PubMed ID: 12750283
[TBL] [Abstract] [Full Text] [Related]
15. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
[TBL] [Abstract] [Full Text] [Related]
16. Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11.
Ogasawara H; Nishio K; Kanzawa F; Lee YS; Funayama Y; Ohira T; Kuraishi Y; Isogai Y; Saijo N
Jpn J Cancer Res; 1995 Jan; 86(1):124-9. PubMed ID: 7737904
[TBL] [Abstract] [Full Text] [Related]
